Loading stock data…
ICCC
$9.77+0.07 (+0.72%)
After Hours$9.77+0.00 (+0.00%)· Last close Jun 9
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ImmuCell Corporation in the Healthcare sector is trading at $9.77. The stock is currently near its 52-week high of $10.75, remaining 45.4% above its 200-day moving average. On fundamentals, Piotroski 8/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 85/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$9.77
Potential Downside
0%
Whystock Fair Value$9.77
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that improves the health and productivity of dairy and beef cattle in the United States and internationally. It operates through two segments, Scours and Masti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-1.87%
Volume
Today's trading volume
17,964
Recent News
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
ICCC posts record Q1 sales and 34% earnings growth as demand for its First Defense calf-health products boosts margins and market share.
ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth
ImmuCell Corp (ICCC) achieves its first-ever $10 million revenue quarter, driven by strong domestic sales and strategic product expansions.
ImmuCell Q1 Earnings Call Highlights
ImmuCell (NASDAQ:ICCC) reported a record first quarter of 2026, with management saying the company’s narrowed focus on its First Defense calf scours prevention portfolio helped drive its first-ever quarter above $10 million in product sales. President and Chief Executive Officer Olivier te Boekhors
Here’s Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity
Minot Light Capital Partners, an investment management company, released its “Capital Appreciation Fund” Q1 2026 Investor Letter. A copy of the letter can be downloaded here. The fund declined by 2.7% in the first quarter of 2026 due to a sharp macro-driven sector rotation following geopolitical tensions, which triggered inflation fears and rising interest rate […]
The Zacks Analyst Blog The Goldman Sachs, NextEra, Shopify, Landmark and ImmuCell
Goldman Sachs, NextEra Energy and Shopify lead top stock reports, highlighting strong gains, expanding operations and strategic shifts driving growth.